Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySirukumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Sirukumab
- Accession Number
- DB11803
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- Categories
- UNII
- 640443FU93
- CAS number
- 1194585-53-9
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Sirukumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Sirukumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab. Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sirukumab. Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirukumab. Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sirukumab. Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Sirukumab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirukumab. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Sirukumab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirukumab. - Food Interactions
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Healthy Volunteers 1 1 Completed Basic Science Rheumatoid Arthritis 1 2 Completed Treatment Major Depressive Disorder (MDD) 1 2 Completed Treatment Rheumatoid Arthritis 1 2 Withdrawn Treatment Asthma Bronchial 1 3 Completed Treatment Rheumatoid Arthritis 5 3 Terminated Treatment Giant Cells Arteritis 1 3 Withdrawn Treatment Polymyalgia Rheumatica 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Drug created on October 20, 2016 14:49 / Updated on October 01, 2018 15:05